- Conditions
- Cholestasis, Liver Diseases
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Catherine Cibulskis, MD
- Other
- Eligibility
- Up to 1 Year
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- La Jolla, California • Sacramento, California • Miami, Florida + 4 more
- Conditions
- Pancreatic Diseases, Bile Duct Obstruction, Bile Duct Diseases
- Interventions
- SpyGlass™ Discover Digital System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- San Diego, California
- Conditions
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Interventions
- Maralixibat, Placebo
- Drug · Other
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more
- Conditions
- Parenteral Nutrition-Associated Liver Disease
- Interventions
- Intravenous fat emulsion, Restriction of intravenous fat emulsion to 1 gm/kg/d
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Hours to 48 Hours
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parenteral Nutrition, Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
- Interventions
- Remove Mn from PN if evidence of increased brain Mn on MRI
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 30 Days to 6 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alagille Syndrome
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Pentoxifylline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven, Omegaven
- Dietary Supplement · Drug
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- 14 Days to 2 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- NGM282, Placebo
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
- Conditions
- Cholestasis, Liver Disease
- Interventions
- Enteral fish oil, Ursodeoxycholic Acid, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 14 Days to 24 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Primary Biliary Cholangitis, Liver Stiffness
- Interventions
- Setanaxib, Placebo
- Drug
- Lead sponsor
- Calliditas Therapeutics Suisse SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Los Angeles, California • Pasadena, California + 23 more
- Conditions
- PFIC1, PFIC2
- Interventions
- A4250 (odevixibat), Placebo
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven IV lipid emulsion
- Drug
- Lead sponsor
- Sivan Kinberg
- Other
- Eligibility
- 2 Months to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cholestasis
- Interventions
- Omega-3 fish oil lipid emulsion
- Drug
- Lead sponsor
- Kapiolani Medical Center For Women & Children
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- NGM282
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more
- Conditions
- Cholestasis
- Interventions
- Intralipid
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 1 Minute to 5 Days
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California • St Louis, Missouri
- Conditions
- Biliary Stricture
- Interventions
- Temperature-sensitive radiofrequency ablation, No intervention
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
- Interventions
- Livmarli
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Alagille Syndrome
- Interventions
- maralixibat
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Months and older
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Redwood City, California • San Francisco, California + 11 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California